PHAT vs ZBH · rev $132.6M vs P/E 23, rev $4.26B
Phathom Pharmaceuticals Inc (PHAT) versus Zimmer Biomet Holdings Inc (ZBH) — a side-by-side from cached financials, not a winner call.
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
Latest reported PHAT revenue for 2026-06-30 was $132.6M. Net income was -$48.0M. PHAT currently screens at market cap $622.7M.
Latest reported ZBH revenue for 2026-06-30 was $4.26B. Net income was $436.5M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
PHAT currently screens at market cap $622.7M. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
Not investment advice. Open the PHAT and ZBH stock pages for the full models.
Not investment advice.